- Home
- SPAI vs XGN Comparison
SPAI vs XGN Comparison
Compare SPAI & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | XGN |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 71.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SPAI | XGN |
|---|---|---|
| Price | $6.02 | $4.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $10.00 | $8.86 |
| AVG Volume (30 Days) | 351.1K | ★ 583.1K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,060.58 | $8.12 |
| Revenue Next Year | $162.46 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.47 | $2.59 |
| 52 Week High | $9.16 | $12.23 |
Technical Indicators
Market Signals| Indicator | SPAI | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.96 | 65.40 |
| Support Level | $3.66 | $2.68 |
| Resistance Level | $7.39 | $6.75 |
| Average True Range (ATR) | 0.55 | 0.40 |
| MACD | 0.22 | 0.12 |
| Stochastic Oscillator | 76.48 | 69.78 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.